S5 - Therapeutics in ALS and SMA
| Event Time: | Sunday May 5, 2019 1:00 pm to 3:00 pm |
| Topic(s): | Neuromuscular and Clinical Neurophysiology (EMG) |
| Director(s): | |
| Description: | |
| Completion Message: | |
| CME Credits: | 2 |
| Core Competencies: |
| Start/End Time | Title | Faculty |
|---|---|---|
| 2:40 PM - 3:00 PM | Q&A Panel with Authors | Faculty |
| Speaker | Disclosure |
|---|
| Start Time | Pub. | Title | Presenter |
|---|---|---|---|
| 1:00 PM | 001 | Intrathecal nusinersen in older children and adults with spinal muscular atrophy |
Disclosure: Dr. Veerapandiyan has nothing to disclose.
|
| 1:00 PM | 002 | Update of FORTITUDE-ALS: A Phase 2, Double-blind, Randomized, Placebo-Controlled, Study to Evaluate Efficacy, Safety and Tolerability of Reldesemtiv in Patients with Amyotrophic Lateral Sclerosis |
Disclosure: Dr. Shefner has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Cytokinetics, Biogen-Idec, Biohaven, Pharnext, MT Pharma America. Dr. Shefner has received personal compensation in an editorial capacity for Neuromuscular Section Editor for UpToDate. Dr. Shefner received financial support for research activities from Cytokinetics, Amylyx, Biogen, Biohaven, Neuraltus, BIotie, Orphazyme, Orrion.
|
| 1:00 PM | 003 | Intrathecal AAV9-SOD1-shRNA Administration for Amyotrophic Lateral Sclerosis |
Disclosure: Employee of AveXis Yes from AveXis Research support from AveXis, a Novartis company.
|
| 1:00 PM | 004 | Cancer Drug Repurposing for Treating Amyotrophic Lateral Sclerosis (ALS) |
Disclosure: Dr. Lukas has nothing to disclose.
|
| 1:00 PM | 005 | A Phase 1 Study to Evaluate Bioequivalence Between BHV-0223 40 mg Zydis® Sublingual Formulation and Riluzole 50 mg Oral Tablet in Healthy Volunteers |
Disclosure: Dr. Qureshi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biohaven Pharmaceuticals. Dr. Qureshi holds stock and/or stock options in Biohaven Pharmaceuticals.
|
| 1:00 PM | 006 | General Characteristics of edaravone Use in the Natural History of ALS and Other Motor Neuron Disorders Consortium Dataset (NeuroBANK™) |
Disclosure: Dr. Arcila-Londono has nothing to disclose.
|
| 1:00 PM | 007 | Nusinersen Treatment in Adults with SMA - the First Year Experience at a Large Center |
Disclosure: Dr. Drory has received personal compensation for consulting serving on a scientific advisory board speaking or other activities with Biogen.
|
| 1:00 PM | 008 | Outcome measures for Nusinersen efficacy in Adults with Spinal Muscular Atrophy |
Disclosure: Dr. Yeo has nothing to disclose.
|
| 1:00 PM | 009 | Prospective open-label study of Nusinersen treatment for adults with Spinal Muscular Atrophy |
Disclosure: Dr. Elsheikh has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Stealth Bio-therapeutics, Biogen. Dr. Elsheikh has received research support from Cure SMA, Biogen.
|
Ready to register for the 2019 AAN Annual Meeting?
Related Courses
| 9:30 AM-11:30 AM |
|---|
|
C12 -
Clinical Approach to Muscle Disease I: Role of Antibodies, Muscle Imaging, and Genetic Testing
Tahseen Mozaffar MD, FAAN |
| 1:30 PM-3:30 PM |
|
C25 -
Clinical Approach to Muscle Disease II: Inflammatory Myopathies and Muscle Pathology
Tahseen Mozaffar MD, FAAN |
| 7:00 AM-9:00 AM |
|---|
|
C46 -
Actualización en dolor de cabeza y trastornos neuromusculares (Update: Headache and Neuromuscular Disorder)
Dario Beltran MD, FAAN, Jose Merino MD, MPhil, FAAN |
|
C36 -
Mastering EMG Waveform Recognition Skills in Just Two Hours!
Devon Rubin MD, FAAN |
| 1:00 PM-3:00 PM |
|
C49 -
Neurology Update I: Multiple Sclerosis, Sleep, and Neuromuscular Disease
Ralph Jozefowicz MD, FAAN, Adam Quick MD |
|
C47 -
Evaluation and Management of Autonomic Disorders I: Autonomic Testing, Failure, and Peripheral Neuropathies
Amanda Peltier MD, MS |
| 3:30 PM-5:30 PM |
|
C65 -
Evaluation and Management of Autonomic Disorders II: Diagnostic Approach and Treatments for Dysautonomia
Amanda Peltier MD, MS |
| 11:30 AM-6:30 PM |
|---|
|
P2 -
Poster Session 2
|
| 1:00 PM-3:00 PM |
|
C101 -
Clinical EMG I: Principles and Practice of NCS and Needle EMG
Ruple Laughlin MD, FAAN |
|
N2 -
Neuroscience in the Clinic: Interpretations of Genetic Results
Karen Marder MD, MPH, FAAN, Massimo Pandolfo MD, FAAN |
| 3:30 PM-4:45 PM |
|
S18 -
Autonomic Disorders
|
| 3:30 PM-5:30 PM |
|
C120 -
Clinical EMG II: Case-based Clinical Applications of Nerve Conduction Studies and Needle Electromyography
Ruple Laughlin MD, FAAN |
|
S23 -
Genetic Muscle Disorders
|
| 7:00 AM-9:00 AM |
|---|
|
C121 -
Clinical EMG III: Nerve Conduction Criteria and Electrodiagnostic Approaches
Mark Bromberg MD, PhD, FAAN |
| 9:15 AM-11:30 AM |
|
Clinical Trials Plenary Session
Deborah Hall MD, PhD, FAAN, Holly Hinson MD, MCR, FAAN |
| 11:30 AM-6:30 PM |
|
P3 -
Poster Session 3
|
| 1:00 PM-3:00 PM |
|
C131 -
Small Fiber Neuropathies: Sensory, Autonomic, and Both I: Focus on Autonomic Nervous System
Christopher Gibbons MD, FAAN |
|
S25 -
Child Neurology: Spinal Muscular Atrophy: Treatments and Outcomes
|
| 1:00 PM-5:30 PM |
|
C148 -
Skills Workshop: EMG: Basic
(Registration Required)
Holli Horak MD, FAAN |
| 3:30 PM-5:30 PM |
|
C150 -
Small Fiber Neuropathies: Sensory, Autonomic, and Both II: Focus on Sensory Nervous System
Christopher Gibbons MD, FAAN |
|
Presentation of the Sheila Essey Award: An Award for ALS Research
|
| 7:00 AM-9:00 AM |
|---|
|
C171 -
Child Neurology: Neuromuscular/Autoimmune Neurology
Anne Connolly MD, FAAN |
| 11:30 AM-6:30 PM |
|
P4 -
Poster Session 4
|
| 1:00 PM-3:00 PM |
|
C175 -
Neuromuscular Junction Disorders I: Myasthenia Gravis, Ocular, and MuSK Myasthenia
Laura Tormoehlen MD, FAAN |
|
N4 -
Neuroscience in the Clinic: Immunotherapies in Neurological Disease
John Corboy MD, FAAN, Holly Hinson MD, MCR, FAAN |
| 1:00 PM-5:30 PM |
|
C191 -
Skills Workshop: Neuromuscular Ultrasound
(Registration Required)
Craig Zaidman MD |
| 3:30 PM-5:30 PM |
|
C192 -
Neuromuscular Junction Disorders II: Toxins, Lambert-Eaton Syndrome and Less Common Disorders of Neuromuscular Transmission
Laura Tormoehlen MD, FAAN |
|
C195 -
Therapy in Neurology II: Neurocritical Care and Neuromuscular Disease
Madhu Soni MD, FAAN |
|
S42 -
Neuromuscular Disorders
|
| 7:00 AM-9:00 AM |
|---|
|
C205 -
Peripheral Neuropathy I: Anatomical Basis and Acquired Demyelinating Neuropathies
David Herrmann MD, FAAN |
|
C214 -
Child Neurology: A Case-based Approach
Elaine Wirrell MD, FAAN |
| 11:30 AM-6:30 PM |
|
P5 -
Poster Session 5
|
| 1:00 PM-3:00 PM |
|
C215 -
Peripheral Neuropathy II: Update on Diabetic, Immune Axonal, and Hematologic-related Neuropathies
Michelle Mauermann MD, FAAN |
| 3:30 PM-5:30 PM |
|
C229 -
Peripheral Neuropathy III: Genetic Neuropathies: Molecular Diagnosis and Treatment Perspectives
Mario Saporta MD, PhD, FAAN |
|
S54 -
Motor Neuron Disease
|
| 7:00 PM-10:00 PM |
|
C237 -
Case Studies: Diagnosis and Management of Unusual Cases in Neuromuscular Disease
Robert Pascuzzi MD, FAAN |
| 7:00 AM-9:00 AM |
|---|
|
C243 -
Therapy of Neuromuscular Disease: ALS, Inflammatory Neuropathies and Myopathies, and Myasthenia Gravis
Michael Weiss MD, FAAN |
| 9:15 AM-11:30 AM |
|
Neurology Year in Review Plenary Session
Martinson Arnan MD |
| 1:00 PM-3:00 PM |
|
S58 -
Therapeutics in Neuromuscular Disorders
|
| 2:00 PM-2:45 PM |
|
Consensus-based Care Recommendations for Adults with Myotonic Dystrophy Type 1
Nicholas Johnson MD, FAAN |
|
Consensus-Based Care Recommendations for Adults with haha
|